Decitabine improves patient outcomes in myelodysplastic syndromes

@article{Kantarjian2006DecitabineIP,
  title={Decitabine improves patient outcomes in myelodysplastic syndromes},
  author={Hagop M. Kantarjian and Jean-Pierre J. Issa and Craig S. Rosenfeld and John M. Bennett and Maher Albitar and John F Dipersio and Virginia M. Klimek and James L. Slack and Carlos M. de Castro and Farhad Ravandi and Richard A Helmer and Lanlan Shen and Stephen D. Nimer and Richard D. Leavitt and Azra Raza and Hussain I. Saba},
  journal={Cancer},
  year={2006},
  volume={106}
}
BACKGROUND Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy. [] Key Method Response was assessed using the International Working Group criteria and required that response criteria be met for at least 8 weeks.

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome

Therapy for patients with myelodysplastic syndrome with hypomethylating agents, like decitabine and 5‐azacitidine, has produced favorable results and cytogenetic response patterns and prognostic factors associated with decitABine therapy are analyzed.

How I treat patients with myelodysplastic syndromes.

Critical issues in determining therapeutic strategies for patients with myelodysplastic syndromes (MDSs), who usually die of bone marrow failure with or without conversion to acute myeloid leukemia

Meta-analysis on hypomethylating agents in myelodysplastic syndromes

The addition of hypomethylating agents into the armatorium against myelodysplastic syndromes (MDS) is commonly accepted as a promising new therapeutic option in this otherwise frustrating field.

Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome

This study aims to explore the association between Dab2 methylation status and expression in newly diagnosed myelodysplastic syndrome patients and patients who received 5‐aza‐2′‐deoxycytidine (decitabine) treatment, so as to determine the effect of Dab1 in the pathogenesis of MDS.

Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management

The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia

Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management

The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia

Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors

Although decitabine, an epigenetically active agent, has mainly been evaluated in the management of hematologic malignancies in adults, safety in children has also been demonstrated repeatedly.

Myelodysplastic syndromes: 2011 update on diagnosis, risk‐stratification, and management

The myelodysplastic (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML).

IRAK Family Kinases as Therapeutic Targets for Myelodysplastic Syndrome and Acute Myeloid Leukemia

The aim of this study was to evaluate the role of IRAK deregulation in hematologic malignancies and the development of novel therapies for AML and to describe the pathways leading to these responses.
...

References

SHOWING 1-10 OF 32 REFERENCES

Results of decitabine (5‐aza‐2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

This study evaluated the activity and toxicity of decitabine in different phases of CML.

First Report of the Phase III North American Trial of Decitabine in Advanced Myelodysplastic Syndrome (MDS).

DAC appears a promising therapy for MDS with manageable toxicity, and Kaplan Meier (KM) curves for time to AML progression or death showed early and clinically meaningful separation in favor of DAC in all patients (intent to treat; ITT), Int-2/High Risk, and High Risk patients.

Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS).

Prospective analysis of the importance of the plasma levels of beta-2 microglobulin (B2M) in 553 patients with myelodysplastic syndrome (MDS) found that B2M is an independent prognostic variable for

Cytogenetic responses in high‐risk myelodysplastic syndrome following low‐dose treatment with the DNA methylation inhibitor 5‐aza‐2′‐deoxycytidine

Repeated courses of low‐dose decitabine induce cytogenetic remissions in a substantial number of elderly MDS patients with pre‐existing chromosomal abnormalites; these are associated with improved survival compared with patients in whom the cytogenetically abnormal clone persists.

DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.

Treatment with demethylating agents, 5-azacytidine and decitabine, at present results in significantly higher response rates, improved quality of life, reduced risk of leukemic transformation, and improved survival, when compared to supportive care.

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Aza C treatment results in significantly higher response rates, improved quality of life, reduced risk of leukemic transformation, and improved survival compared with supportive care.

International scoring system for evaluating prognosis in myelodysplastic syndromes.

Compared with prior risk-based classifications, this International Prognostic Scoring System provides an improved method for evaluating prognosis in MDS and should prove useful for more precise design and analysis of therapeutic trials in this disease.

Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes

Purpose: This article summarizes data submitted to the U.S. Food and Drug Administration for marketing approval of azacitidine as injectable suspension (Vidaza, Pharmion Corporation, Boulder, CO) for

Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome

It is concluded that DAC is an effective drug in the treatment of MDS patients and that it probably works via its cytotoxic activity, with myelotoxicity being its major adverse effect.